Allospecific CD154 + T-cytotoxic memory cells as potential surrogate for rejection risk in pediatric intestine transplantation

Pediatric Transplantation

Volumn 16, Issue 1, 2012, Pages 83-91

  Sindhi, Rakesh ^a,b   Ashokkumar, Chethan ^a,b   Higgs, Brandon W ^a,b   Gilbert, P B ^c   Sun, Qing ^a,b   Ranganathan, Sarangarajan ^d   Jaffe, Ron ^d   Snyder, Sara ^a,b   Ningappa, Mylarappa ^a,b   Soltys, Kyle A ^a,b   Bond, Geoffrey J ^a,b   Mazariegos, George V ^a,b   Abu Elmagd, Kareem ^a,b   Zeevi, Adriana ^d  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

anti lymphocyte antibodies; biomarker; children; clinical trials; immunosuppression; intestine transplantation; surrogate marker

Indexed keywords

ALEMTUZUMAB; ALLOANTIGEN; CD40 LIGAND; PREDNISONE; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; DISEASE MARKER; DISEASE SEVERITY; DRUG DOSE REDUCTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; INTESTINE TRANSPLANTATION; MEMORY T LYMPHOCYTE; PARAMETERS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SIMULATION; SINGLE DRUG DOSE; TREATMENT OUTCOME;

ADOLESCENT; ANTILYMPHOCYTE SERUM; BIOLOGICAL MARKERS; CD40 LIGAND; CHILD; CHILD, PRESCHOOL; GRAFT REJECTION; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOSUPPRESSIVE AGENTS; INFANT; INTESTINES; PEDIATRICS; RISK; SENSITIVITY AND SPECIFICITY; T-LYMPHOCYTES; TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 84856018103     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2011.01617.x     Document Type: Article

References (23)

1. Shirkey H,. Therapeutic orphans. J Pediatr 1968: 72: 119-120.
2. Horen B, Montastruc JL, Lapeyre-Mestre M,. Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol 2002: 54: 665-670. (Pubitemid 36002596)
3. UNOS OPTN A nnual R eport. 2008 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 2008. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Health Care Systems Bureau, Division of Transplantation; Richmond, VA: United Network for Organ Sharing; Ann Arbor, MI: University Renal Research and Education Association, 2008.
4. Nayyar N, Mazariegos GV, Ranganathan S, et al., Pediatric small bowel transplantation. Semin Pediatr Surg 2010: 19: 68-77.
5. Patel R, Terasaki PI,. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969: 280: 735-739.
6. Gebauer BS, Hricik DE, Atallah A, et al., Evolution of the enzyme-linked immunosorbent spot assay for post-transplant alloreactivity as a potentially useful immune monitoring tool. Am J Transplant 2002: 2: 857-866. (Pubitemid 36306841)
7. Li B, Hartono C, Ding R, et al., Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med 2001: 344: 947-954. (Pubitemid 32240312)
8. Chattopadhyay PK, Yu J, Roederer M,. A live-cell assay to detect antigen-specific CD4 + T cells with diverse cytokine profiles. Nat Med 2005: 11: 1113-1117. (Pubitemid 41486835)
9. Ashokkumar C, Talukdar A, Sun Q, et al., Allospecific CD154 + T cells associate with rejection risk after pediatric liver transplantation. Am J Transplant 2009: 9: 179-191.
10. Ashokkumar C, Gupta A, Sun Q, et al., Allospecific CD154 + T-cells identify rejection-prone recipients after pediatric small-bowel transplantation. Surgery 2009: 146: 166-173.
11. Iwakoshi NN, Mordes JP, Markees TG, Phillips NE, Rossini AA, Greiner DL,. Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8 + T cells and prolonged graft survival in a CTLA4-dependent manner. J Immunol 2000: 164: 512-521. (Pubitemid 30013028)
12. Koyama I, Nadazdin O, Boskovic S, et al., Depletion of CD8 memory T cells for induction of tolerance of a previously transplanted kidney allograft. Am J Transplant 2007: 5: 1055-1061. (Pubitemid 46643090)
13. Shapiro R, Ellis D, Tan HP, et al., Alemtuzumab pre-conditioning with tacrolimus monotherapy in pediatric renal transplantation. Am J Transplant 2007: 7: 2736-2738. (Pubitemid 350045765)
14. Reyes J, Mazariegos GV, Abu-Elmagd K, et al., Intestinal transplantation under tacrolimus monotherapy after perioperative lymphoid depletion with rabbit anti-thymocyte globulin (thymoglobulin). Am J Transplant 2005: 5: 1430-1436. (Pubitemid 40839435)
15. Wu T, Abu-Elmagd K, Bond GJ, Nalesnik MA, Randhawa P, Demetris AJ,. A schema for histologic grading of small intestine allograft acute rejection. Transplantation 2003: 75: 1241-1248. (Pubitemid 36513028)
16. Prentice RL,. Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med 1989: 8: 431-440. (Pubitemid 19105891)
17. Berger VW,. Does the Prentice criterion validate surrogate endpoints? Stat Med 2004: 23: 1571-1578. (Pubitemid 38660409)
18. Fleming TR,. Surrogate endpoints and FDA's accelerated approval process. Health Aff 2005: 24: 67-78. (Pubitemid 40173935)
19. The members of the Tricontinental Mycophenolate Mofetil Renal Transplantation Executive Committee and Study Group. Executive Committee:, Keown P, Häyry P, Mathew T, et al., Study Group:, Keown P, Landsberg D, Hardie I, et al., A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996: 61: 1029-1037. (Pubitemid 26120252)
20. MacDonald AS,; RAPAMUNE G lobal S tudy G roup. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001: 71: 271-280. (Pubitemid 32126112)
21. Larsen CP, Grinyõ J, Medina-Pestana J, et al., Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation 2010: 90: 1528-1535.
22. Qin L, Gilbert PB, Corey L, Mcelrath MJ, Self SG,. A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis 2007: 196: 1304-1312. (Pubitemid 351412002)
23. Khera N, Janosky J, Zeevi A, Mazariegos GV, Marcos A, Sindhi R,. Persistent donor-specific alloreactivity may portend delayed liver rejection during drug minimization in children. Front Biosci 2007: 2: 660-663. (Pubitemid 46852812)